Status:
RECRUITING
A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Lead Sponsor:
Takeda
Conditions:
Cytomegalovirus (CMV)
Eligibility:
All Genders
12+ years
Brief Summary
The main aim of this study is to learn about the safety of Maribavir in adults and children with post-transplant CMV infection in routine clinical practice in Argentina. The other aim is to study the...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult participants (18 years or older) and pediatric participants (12 years of age and older and weighing at least 35 kilogram \[kg\]) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in the real-world setting of common clinical practice in Argentina.
- Have received at least one dose of maribavir according to approved indications.
- Have signed the mandatory informed consent/assent that has been agreed with national regulatory authorities (ANMAT) as applicable.
- Exclusion Criteria
- \- There are no specific exclusion criteria.
Exclusion
Key Trial Info
Start Date :
September 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06213974
Start Date
September 3 2024
End Date
September 1 2026
Last Update
July 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IC Projects
City of Buenos Aires, Argentina, C11119ACN